Announcements Trials
Browse Landscape

Status

Completed 71Terminated 37Recruiting 18Unknown 14Active not recruiting 8Withdrawn 4Not yet recruiting 4No longer available 2Available 2Suspended 1

Sponsor Class

INDUSTRY 2

Study Type

Expanded_access 2

Sponsor

Cancer Type

Gastrointestinal 2Sarcoma 1Lymphoid 1Gynecologic 1Genitourinary 1CNS 1Breast 1

Conditions

Neoplasms 7Carcinoma, Non-Small-Cell Lung 7Sarcoma 5Pancreatic Neoplasms 5Multiple Myeloma 5Melanoma 5Prostatic Neoplasms 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Ovarian Neoplasms 3Lymphoma, Large B-Cell, Diffuse 3Leukemia, Myeloid, Acute 3Glioblastoma 3Breast Neoplasms 3Urinary Bladder Neoplasms 2Stomach Neoplasms 2Small Cell Lung Carcinoma 2Recurrence 2Primary Myelofibrosis 2Non-Muscle Invasive Bladder Neoplasms 2Neuroblastoma 2Neoplasm Metastasis 2Lymphoma, T-Cell, Peripheral 2Lymphoma, Non-Hodgkin 2Lymphoma, Follicular 2Lymphoma 2Head and Neck Neoplasms 2Gastrointestinal Neoplasms 2Colorectal Neoplasms 2Cholangiocarcinoma 2Carcinoma, Transitional Cell 2

Interventions

Proton Pump Inhibitors 1Hydrocortisone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Available × INDUSTRY × Carcinoma, Squamous Cell × Clear all
NCT06910137 2026-01-08

An Early Access Program Guideline to Provide Access to Retifanlimab (INCMGA00012) Together With Carboplatin and Paclitaxel for Squamous Carcinoma of the Anal Canal (SCAC)

Incyte Corporation

Available
Gastrointestinal

Anus Neoplasms, Carcinoma, Squamous Cell

NCT05974410 2025-10-02

Expanded Access to Immunomodulatory AVM0703 for Solid Tumor and Blood Cancer Patients

AVM Biotechnology Inc

Available
BreastCNSGastrointestinalGenitourinaryGynecologicLymphoidSarcoma

Brain Neoplasms, Breast Neoplasms, Carcinoma, Squamous Cell, Glioblastoma, Hodgkin Disease, Lymphoma, Non-Hodgkin, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡